PDF herunterladen
Semin Liver Dis 2022; 42(04): 501-513
DOI: 10.1055/a-1942-6693
Review Article

Hepatocellular Carcinoma Chemoprevention with Generic Agents

Fahmida Rasha
1   Liver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas
,
Subhojit Paul
1   Liver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas
,
Tracey G. Simon
2   Liver Center, Division of Gastroenterology, Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
,
Yujin Hoshida
1   Liver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas
› Institutsangaben Funding Funding received from Cancer Prevention and Research Institute of Texas (RR180016, RP200554); U.S. Department of Health and Human Services, National Institutes of Health, Center for Scientific Review (CA233794, CA127003, CA226052, CA255621, DK122104); European Commission (ERC-2014-AdG-671231, ERC-2020-ADG-101021417)
› Weitere Informationen
    Lizenzen und Reprints


Abstract

Liver cancer, mainly hepatocellular carcinoma (HCC), remains a major cause of cancer-related death worldwide. With the global epidemic of obesity, the major HCC etiologies have been dynamically shifting from viral to metabolic liver diseases. This change has made HCC prevention difficult with increasingly elusive at-risk populations as rational target for preventive interventions. Besides ongoing efforts to reduce obesity and metabolic disorders, chemoprevention in patients who already have metabolic liver diseases may have a significant impact on the poor HCC prognosis. Hepatitis B– and hepatitis C–related HCC incidences have been substantially reduced by the new antivirals, but HCC risk can persist over a decade even after successful viral treatment, highlighting the need for HCC-preventive measures also in these patients. Experimental and retrospective studies have suggested potential utility of generic agents such as lipophilic statins and aspirin for HCC chemoprevention given their well-characterized safety profile, although anticipated efficacy may be modest. In this review, we overview recent clinical and translational studies of generic agents in the context of HCC chemoprevention under the contemporary HCC etiologies. We also discuss newly emerging approaches to overcome the challenges in clinical testing of the agents to facilitate their clinical translation.

Keywords

generic agent - hepatocellular carcinoma - chemoprevention - biomarker - drug repurposing


Publikationsverlauf

Accepted Manuscript online:
14. September 2022

Artikel online veröffentlicht:
14. Oktober 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Ferlay J, Colombet M, Soerjomataram I. et al. Cancer statistics for the year 2020: an overview. Int J Cancer 2021; 149: 778-789 DOI: 10.1002/ijc.33588.
    CrossrefPubMedGoogle Scholar
  • 2 Lee YT, Wang JJ, Luu M. et al. State-level HCC incidence and association with obesity and physical activity in the United States. Hepatology 2021; 74 (03) 1384-1394
    CrossrefPubMedGoogle Scholar
  • 3 Reig M, Forner A, Rimola J. et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 2022; 76 (03) 681-693
    CrossrefPubMedGoogle Scholar
  • 4 Lee YT, Wang JJ, Luu M. et al. The mortality and overall survival trends of primary liver cancer in the United States. J Natl Cancer Inst 2021; 113 (11) 1531-1541
    CrossrefPubMedGoogle Scholar
  • 5 Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab 2022; 34 (07) 969-977.e2
    CrossrefPubMedGoogle Scholar
  • 6 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64 (01) 73-84
    CrossrefPubMedGoogle Scholar
  • 7 Liu J, Ayada I, Zhang X. et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol 2022; 20 (03) e573-e582
    CrossrefPubMedGoogle Scholar
  • 8 Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018; 68 (03) 526-549
    CrossrefPubMedGoogle Scholar
  • 9 Baumert TF, Jühling F, Ono A, Hoshida Y. Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med 2017; 15 (01) 52
    CrossrefPubMedGoogle Scholar
  • 10 Lockart I, Yeo MGH, Hajarizadeh B, Dore GJ, Danta M. HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis. Hepatology 2022; 76 (01) 139-154
    CrossrefPubMedGoogle Scholar
  • 11 Kim NJ, Vutien P, Cleveland E, Cravero A, Ioannou GN. Fibrosis stage-specific incidence of hepatocellular cancer after hepatitis C cure with direct-acting antivirals: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2022; (e-pub ahead of print). DOI: 10.1016/j.cgh.2022.04.013.
    CrossrefPubMedGoogle Scholar
  • 12 Tan DJH, Ng CH, Tay PWL. et al. Risk of hepatocellular carcinoma with tenofovir vs entecavir treatment for chronic hepatitis B virus: a reconstructed individual patient data meta-analysis. JAMA Netw Open 2022; 5 (06) e2219407
    CrossrefPubMedGoogle Scholar
  • 13 Nahon P, Vo Quang E, Ganne-Carrié N. Stratification of hepatocellular carcinoma risk following HCV eradication or HBV control. J Clin Med 2021; 10 (02) 353
    CrossrefPubMedGoogle Scholar
  • 14 Wen N, Cai Y, Li F. et al. The clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines: 2022 update. Biosci Trends 2022; 16 (01) 20-30
    CrossrefPubMedGoogle Scholar
  • 15 Parikh ND, Singal AG, Hutton DW. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma. Cancer 2017; 123 (19) 3725-3731
    CrossrefPubMedGoogle Scholar
  • 16 Loomans-Kropp HA, Umar A. Cancer prevention and screening: the next step in the era of precision medicine. NPJ Precis Oncol 2019; 3: 3
    CrossrefPubMedGoogle Scholar
  • 17 Athuluri-Divakar SK, Hoshida Y. Generic chemoprevention of hepatocellular carcinoma. Ann N Y Acad Sci 2019; 1440 (01) 23-35
    CrossrefPubMedGoogle Scholar
  • 18 Lippman SM, Abate-Shen C, Colbert Maresso KL. et al. AACR white paper: shaping the future of cancer prevention - a roadmap for advancing science and public health. Cancer Prev Res (Phila) 2018; 11 (12) 735-778
    CrossrefPubMedGoogle Scholar
  • 19 Simon TG, Roelstraete B, Sharma R, Khalili H, Hagström H, Ludvigsson JF. Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease: a population-based cohort study. Hepatology 2021; 74 (05) 2410-2423
    CrossrefPubMedGoogle Scholar
  • 20 Sanyal AJ, Van Natta ML, Clark J. et al; NASH Clinical Research Network (CRN). Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med 2021; 385 (17) 1559-1569
    CrossrefPubMedGoogle Scholar
  • 21 Mittal S, El-Serag HB, Sada YH. et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2016; 14 (01) 124-31.e1
    CrossrefPubMedGoogle Scholar
  • 22 PDQ® Screening and Prevention Editorial Board. PDQ Levels of Evidence for Cancer Screening and Prevention Studies. Bethesda, MD: National Cancer Institute; ; Available at: https://www.cancer.gov/publications/pdq/levels-evidence/screening-prevention
    Google Scholar
  • 23 Harris RP, Helfand M, Woolf SH. et al; Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001; 20 (3, Suppl): 21-35
    CrossrefPubMedGoogle Scholar
  • 24 Shankaraiah RC, Gramantieri L, Fornari F, Sabbioni S, Callegari E, Negrini M. Animal models of hepatocellular carcinoma prevention. Cancers (Basel) 2019; 11 (11) 11
    CrossrefPubMedGoogle Scholar
  • 25 Lippman SM, Klein EA, Goodman PJ. et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301 (01) 39-51
    CrossrefPubMedGoogle Scholar
  • 26 Guirguis-Blake JM, Evans CV, Perdue LA, Bean SI, Senger CA. Aspirin use to prevent cardiovascular disease and colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2022; 327 (16) 1585-1597
    CrossrefPubMedGoogle Scholar
  • 27 Bruix J, Poynard T, Colombo M. et al; EPIC3 Study Group. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 2011; 140 (07) 1990-1999
    CrossrefPubMedGoogle Scholar
  • 28 Di Bisceglie AM, Shiffman ML, Everson GT. et al; HALT-C Trial Investigators. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359 (23) 2429-2441
    CrossrefPubMedGoogle Scholar
  • 29 Nakagawa S, Wei L, Song WM. et al; Precision Liver Cancer Prevention Consortium. Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition. Cancer Cell 2016; 30 (06) 879-890
    CrossrefPubMedGoogle Scholar
  • 30 Fuchs BC, Hoshida Y, Fujii T. et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology 2014; 59 (04) 1577-1590
    CrossrefPubMedGoogle Scholar
  • 31 Deshmukh M, Nakagawa S, Higashi T. et al; Precision Liver Cancer Prevention Consortium. Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. Nanomedicine 2018; 14 (02) 317-325
    CrossrefPubMedGoogle Scholar
  • 32 Li S, Ghoshal S, Sojoodi M. et al. Pioglitazone reduces hepatocellular carcinoma development in two rodent models of cirrhosis. J Gastrointest Surg 2019; 23 (01) 101-111
    CrossrefPubMedGoogle Scholar
  • 33 Sojoodi M, Wei L, Erstad DJ. et al. Epigallocatechin gallate induces hepatic stellate cell senescence and attenuates development of hepatocellular carcinoma. Cancer Prev Res (Phila) 2020; 13 (06) 497-508
    CrossrefPubMedGoogle Scholar
  • 34 Jühling F, Hamdane N, Crouchet E. et al. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. Gut 2021; 70 (01) 157-169
    CrossrefPubMedGoogle Scholar
  • 35 Crouchet E, Bandiera S, Fujiwara N. et al. A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. Nat Commun 2021; 12 (01) 5525
    CrossrefPubMedGoogle Scholar
  • 36 Kim MH, Kim MY, Salloum S. et al. Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature. Hepatol Commun 2022; 6 (09) 2581-2593
    CrossrefPubMedGoogle Scholar
  • 37 Qian T, Fujiwara N, Koneru B. et al. Molecular signature predictive of long-term liver fibrosis progression to inform antifibrotic drug development. Gastroenterology 2022; 162 (04) 1210-1225
    CrossrefPubMedGoogle Scholar
  • 38 Fujiwara N, Kubota N, Crouchet E. et al. Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. Sci Transl Med 2022; 14 (650) eabo4474
    CrossrefPubMedGoogle Scholar
  • 39 Wooden B, Goossens N, Hoshida Y, Friedman SL. Using big data to discover diagnostics and therapeutics for gastrointestinal and liver diseases. Gastroenterology 2017; 152 (01) 53-67.e3
    CrossrefPubMedGoogle Scholar
  • 40 Tran AA, Prasad V. Drug repurposing for cancer treatments: a well-intentioned, but misguided strategy. Lancet Oncol 2020; 21 (09) 1134-1136
    CrossrefPubMedGoogle Scholar
  • 41 Pushpakom S, Iorio F, Eyers PA. et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 2019; 18 (01) 41-58
    CrossrefPubMedGoogle Scholar
  • 42 Breckenridge A, Jacob R. Overcoming the legal and regulatory barriers to drug repurposing. Nat Rev Drug Discov 2019; 18 (01) 1-2
    CrossrefPubMedGoogle Scholar
  • 43 Tziomalos K, Athyros VG, Paschos P, Karagiannis A. Nonalcoholic fatty liver disease and statins. Metabolism 2015; 64 (10) 1215-1223
    CrossrefPubMedGoogle Scholar
  • 44 Alipour Talesh G, Trézéguet V, Merched A. Hepatocellular carcinoma and statins. Biochemistry 2020; 59 (37) 3393-3400
    CrossrefPubMedGoogle Scholar
  • 45 Facciorusso A, Abd El Aziz MA, Singh S. et al. Statin use decreases the incidence of hepatocellular carcinoma: an updated meta-analysis. Cancers (Basel) 2020; 12 (04) 12
    CrossrefPubMedGoogle Scholar
  • 46 Wang Y, Wang W, Wang M, Shi J, Jia X, Dang S. A meta-analysis of statin use and risk of hepatocellular carcinoma. Can J Gastroenterol Hepatol 2022; 2022: 5389044
    CrossrefPubMedGoogle Scholar
  • 47 Fujiwara N, Kobayashi M, Fobar AJ. et al. A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. Med (N Y) 2021; 2 (07) 836-850.e10
    PubMedGoogle Scholar
  • 48 Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol 2022; 18 (09) 525-539
    CrossrefPubMedGoogle Scholar
  • 49 Plaz Torres MC, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG. Diabetes medications and risk of HCC. Hepatology 2022
    PubMedGoogle Scholar
  • 50 Wabitsch S, McCallen JD, Kamenyeva O. et al. Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. J Hepatol 2022; 77 (03) 748-760
    CrossrefPubMedGoogle Scholar
  • 51 DePeralta DK, Wei L, Ghoshal S. et al. Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. Cancer 2016; 122 (08) 1216-1227
    CrossrefPubMedGoogle Scholar
  • 52 Li Q, Xu H, Sui C, Zhang H. Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus. Clin Res Hepatol Gastroenterol 2022; 46 (02) 101781
    CrossrefPubMedGoogle Scholar
  • 53 Kramer JR, Natarajan Y, Dai J. et al. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology 2022; 75 (06) 1420-1428
    CrossrefPubMedGoogle Scholar
  • 54 Arvind A, Memel ZN, Philpotts LL, Zheng H, Corey KE, Simon TG. Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: a meta-analysis. Metabolism 2021; 120: 154780
    CrossrefPubMedGoogle Scholar
  • 55 Ricciotti E, Wangensteen KJ, FitzGerald GA. Aspirin in hepatocellular carcinoma. Cancer Res 2021; 81 (14) 3751-3761
    CrossrefPubMedGoogle Scholar
  • 56 Ishikawa H, Mutoh M, Sato Y. et al. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial. Lancet Gastroenterol Hepatol 2021; 6 (06) 474-481
    CrossrefPubMedGoogle Scholar
  • 57 Malehmir M, Pfister D, Gallage S. et al. Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat Med 2019; 25 (04) 641-655
    CrossrefPubMedGoogle Scholar
  • 58 Tan RZH, Lockart I, Abdel Shaheed C, Danta M. Systematic review with meta-analysis: the effects of non-steroidal anti-inflammatory drugs and anti-platelet therapy on the incidence and recurrence of hepatocellular carcinoma. Aliment Pharmacol Ther 2021; 54 (04) 356-367
    CrossrefPubMedGoogle Scholar
  • 59 Wang Y, Wang M, Liu C, Wang W, Shi J, Dang S. Aspirin use and the risk of hepatocellular carcinoma: a meta-analysis. J Clin Gastroenterol 2022; 56 (07) e293-e302
    CrossrefPubMedGoogle Scholar
  • 60 Koretz RL. Aspirin use is associated with reduced risk for hepatocellular carcinoma. Ann Intern Med 2022; 175 (07) JC83
    CrossrefPubMedGoogle Scholar
  • 61 Jang H, Lee YB, Moon H. et al. Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. Hepatology 2022; 76 (02) 492-501
    CrossrefPubMedGoogle Scholar
  • 62 Chen H, Cai W, Chu ESH. et al. Hepatic cyclooxygenase-2 overexpression induced spontaneous hepatocellular carcinoma formation in mice. Oncogene 2017; 36 (31) 4415-4426
    CrossrefPubMedGoogle Scholar
  • 63 Xiong H, Li B, He J, Zeng Y, Zhang Y, He F. lncRNA HULC promotes the growth of hepatocellular carcinoma cells via stabilizing COX-2 protein. Biochem Biophys Res Commun 2017; 490 (03) 693-699
    CrossrefPubMedGoogle Scholar
  • 64 Xu Y, Zhao W, Xu J. et al. Activated hepatic stellate cells promote liver cancer by induction of myeloid-derived suppressor cells through cyclooxygenase-2. Oncotarget 2016; 7 (08) 8866-8878
    CrossrefPubMedGoogle Scholar
  • 65 Loo TM, Kamachi F, Watanabe Y. et al. Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity. Cancer Discov 2017; 7 (05) 522-538
    CrossrefPubMedGoogle Scholar
  • 66 Takami Y, Eguchi S, Tateishi M. et al. A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment. Hepatol Int 2016; 10 (05) 799-806
    CrossrefPubMedGoogle Scholar
  • 67 Marron TU, Schwartz M, Corbett V, Merad M. Neoadjuvant immunotherapy for hepatocellular carcinoma. J Hepatocell Carcinoma 2022; 9: 571-581
    CrossrefPubMedGoogle Scholar
  • 68 Marron TU, Fiel MI, Hamon P. et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2022; 7 (03) 219-229
    CrossrefPubMedGoogle Scholar
  • 69 Kaseb AO, Hasanov E, Cao HST. et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2022; 7 (03) 208-218
    CrossrefPubMedGoogle Scholar
  • 70 Qiu SJ, Zhou ZG, Shen F. et al. A multicenter, randomized, observation-controlled clinical trial to evaluate the efficacy and safety of thymalfasin adjuvant therapy in patients with HBV-related HCC after curative resection - first announcement of the protocol. Expert Opin Biol Ther 2015; 15 (Suppl. 01) S133-S137
    CrossrefPubMedGoogle Scholar
  • 71 Linye H, Zijing X, Wei P, Chao H, Chuan L, Tianfu W. Thymosin alpha-1 therapy improves postoperative survival after curative resection for solitary hepatitis B virus-related hepatocellular carcinoma: a propensity score matching analysis. Medicine (Baltimore) 2021; 100 (20) e25749
    CrossrefPubMedGoogle Scholar
  • 72 Chang MH, You SL, Chen CJ. et al; Taiwan Hepatoma Study Group. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterology 2016; 151 (03) 472-480.e1
    CrossrefPubMedGoogle Scholar
  • 73 Huang P, Liu M, Zang F. et al. The development of hepatocellular carcinoma in HCV-infected patients treated with DAA: a comprehensive analysis. Carcinogenesis 2018; 39 (12) 1497-1505
    CrossrefPubMedGoogle Scholar
  • 74 Chen LT, Chen MF, Li LA. et al; Disease Committee of Adjuvant Therapy for Postoperative Hepatocellular Carcinoma, Taiwan Cooperative Oncology Group, National Health Research Institutes, Zhunan, Taiwan. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg 2012; 255 (01) 8-17
    CrossrefPubMedGoogle Scholar
  • 75 Bhurwal A, Rattan P, Yoshitake S. et al. Inverse association of coffee with liver cancer development: an updated systematic review and meta-analysis. J Gastrointestin Liver Dis 2020; 29 (03) 421-428
    PubMedGoogle Scholar
  • 76 Deng Y, Huang J, Wong MCS. Associations between six dietary habits and risk of hepatocellular carcinoma: a Mendelian randomization study. Hepatol Commun 2022; 6 (08) 2147-2154
    CrossrefPubMedGoogle Scholar
  • 77 Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis. BMJ Open 2017; 7 (05) e013739
    CrossrefPubMedGoogle Scholar
  • 78 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69 (01) 182-236
    Google Scholar
  • 79 Bamia C, Lagiou P, Jenab M. et al. Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: multicentre, prospective cohort study. Int J Cancer 2015; 136 (08) 1899-1908
    CrossrefPubMedGoogle Scholar
  • 80 Aleksandrova K, Bamia C, Drogan D. et al. The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2015; 102 (06) 1498-1508
    CrossrefPubMedGoogle Scholar
  • 81 Xiao Q, Sinha R, Graubard BI, Freedman ND. Inverse associations of total and decaffeinated coffee with liver enzyme levels in National Health and Nutrition Examination Survey 1999-2010. Hepatology 2014; 60 (06) 2091-2098
    CrossrefPubMedGoogle Scholar
  • 82 Edling CE, Selvaggi F, Ghonaim R, Maffucci T, Falasca M. Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway. Cancer Biol Ther 2014; 15 (05) 524-532
    CrossrefPubMedGoogle Scholar
  • 83 Duarte-Salles T, Fedirko V, Stepien M. et al. Dietary fat, fat subtypes and hepatocellular carcinoma in a large European cohort. Int J Cancer 2015; 137 (11) 2715-2728
    CrossrefPubMedGoogle Scholar
  • 84 Sawada N, Inoue M, Iwasaki M. et al; Japan Public Health Center-Based Prospective Study Group. Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. Gastroenterology 2012; 142 (07) 1468-1475
    CrossrefPubMedGoogle Scholar
  • 85 Moussa I, Day RS, Li R. et al. Association of dietary fat intake and hepatocellular carcinoma among US adults. Cancer Med 2021; 10 (20) 7308-7319
    CrossrefPubMedGoogle Scholar
  • 86 Jiao J, Kwan SY, Sabotta CM. et al. Circulating fatty acids associated with advanced liver fibrosis and hepatocellular carcinoma in South Texas Hispanics. Cancer Epidemiol Biomarkers Prev 2021; 30 (09) 1643-1651
    CrossrefPubMedGoogle Scholar
  • 87 Liebig M, Dannenberger D, Vollmar B, Abshagen K. n-3 PUFAs reduce tumor load and improve survival in a NASH-tumor mouse model. Ther Adv Chronic Dis 2019; 10: 2040622319872118
    CrossrefPubMedGoogle Scholar
  • 88 Zhang Y, Jiang X, Li X. et al. Serum vitamin D levels and risk of liver cancer: a systematic review and dose-response meta-analysis of cohort studies. Nutr Cancer 2021; 73 (08) 1-9
    CrossrefPubMedGoogle Scholar
  • 89 Bjelakovic G, Nikolova D, Bjelakovic M, Gluud C. Vitamin D supplementation for chronic liver diseases in adults. Cochrane Database Syst Rev 2017; 11: CD011564
    PubMedGoogle Scholar
  • 90 Preziosi ME, Singh S, Valore EV. et al. Mice lacking liver-specific β-catenin develop steatohepatitis and fibrosis after iron overload. J Hepatol 2017; 67 (02) 360-369
    CrossrefPubMedGoogle Scholar
  • 91 Mancuso A. Evidence-based medicine and management of hepatocellular carcinoma in thalassemia. BMC Gastroenterol 2020; 20 (01) 409
    CrossrefPubMedGoogle Scholar
  • 92 Lo EKK, , Felicianna, Xu JH, Zhan Q, Zeng Z, El-Nezami H. The emerging role of branched-chain amino acids in liver diseases. Biomedicines 2022; 10 (06) 1444
    CrossrefPubMedGoogle Scholar
  • 93 Kawaguchi T, Shiraishi K, Ito T. et al. Branched-chain amino acids prevent hepatocarcinogenesis and prolong survival of patients with cirrhosis. Clin Gastroenterol Hepatol 2014; 12 (06) 1012-8.e1
    CrossrefPubMedGoogle Scholar
  • 94 Nojiri S, Fujiwara K, Shinkai N, Iio E, Joh T. Effects of branched-chain amino acid supplementation after radiofrequency ablation for hepatocellular carcinoma: a randomized trial. Nutrition 2017; 33: 20-27
    CrossrefPubMedGoogle Scholar
  • 95 Hachiya H, Aoki T, Iso Y. et al. Effects of branched-chain amino acids on postoperative tumor recurrence in patients undergoing curative resection for hepatocellular carcinoma: a randomized clinical trial. J Hepatobiliary Pancreat Sci 2020; 27 (11) 819-829
    CrossrefPubMedGoogle Scholar
  • 96 Ramani K, Robinson AE, Berlind J. et al. S-adenosylmethionine inhibits la ribonucleoprotein domain family member 1 in murine liver and human liver cancer cells. Hepatology 2022; 75 (02) 280-296
    CrossrefPubMedGoogle Scholar
  • 97 Morgan TR, Osann K, Bottiglieri T. et al. A phase II randomized, controlled trial of S-adenosylmethionine in reducing serum α-fetoprotein in patients with hepatitis C cirrhosis and elevated AFP. Cancer Prev Res (Phila) 2015; 8 (09) 864-872
    CrossrefPubMedGoogle Scholar
  • 98 Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The essential medicinal chemistry of curcumin. J Med Chem 2017; 60 (05) 1620-1637
    CrossrefPubMedGoogle Scholar
  • 99 Luo H, Tang L, Tang M. et al. Phase IIa chemoprevention trial of green tea polyphenols in high-risk individuals of liver cancer: modulation of urinary excretion of green tea polyphenols and 8-hydroxydeoxyguanosine. Carcinogenesis 2006; 27 (02) 262-268
    CrossrefPubMedGoogle Scholar
  • 100 Veldt BJ, Hansen BE, Ikeda K, Verhey E, Suzuki H, Schalm SW. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. Scand J Gastroenterol 2006; 41 (09) 1087-1094
    CrossrefPubMedGoogle Scholar
  • 101 Teng CF, Yu CH, Chang HY. et al. Chemopreventive effect of phytosomal curcumin on hepatitis B virus-related hepatocellular carcinoma in a transgenic mouse model. Sci Rep 2019; 9 (01) 10338
    CrossrefPubMedGoogle Scholar
  • 102 Lim JY, Liu C, Hu KQ. et al. Xanthophyll β-cryptoxanthin inhibits highly refined carbohydrate diet-promoted hepatocellular carcinoma progression in mice. Mol Nutr Food Res 2020; 64 (03) e1900949
    CrossrefPubMedGoogle Scholar
  • 103 Chen Q, Shu C, Laurence AD. et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut 2018; 67 (11) 2006-2016
    CrossrefPubMedGoogle Scholar
  • 104 Qian T, Zhu S, Hoshida Y. Use of big data in drug development for precision medicine: an update. Expert Rev Precis Med Drug Dev 2019; 4 (03) 189-200
    CrossrefPubMedGoogle Scholar
  • 105 Wang Z, Clark NR, Ma'ayan A. Drug-induced adverse events prediction with the LINCS L1000 data. Bioinformatics 2016; 32 (15) 2338-2345
    CrossrefPubMedGoogle Scholar
  • 106 Luo Q, Mo S, Xue Y. et al. Novel deep learning-based transcriptome data analysis for drug-drug interaction prediction with an application in diabetes. BMC Bioinformatics 2021; 22 (01) 318
    CrossrefPubMedGoogle Scholar
  • 107 Geissler EK, Schnitzbauer AA, Zülke C. et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation 2016; 100 (01) 116-125
    Google Scholar
  • 108 Schnitzbauer AA, Filmann N, Adam R. et al. mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors. Ann Surg 2020; 272 (05) 855-862
    Google Scholar
  • 109 Crouchet E, Li S, Sojoodi M. et al. Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation. JCI Insight 2022; 7 (13) 7
    CrossrefPubMedGoogle Scholar
  • 110 Asgharzadeh F, Jafarzadeh-Esfehani R, Hassanian SM, Ferns GA, Avan A, Khazaei M. Renin-angiotensin system inhibitors and development of hepatocellular carcinoma: a systematic review and meta-analysis. Curr Pharm Des 2020; 26 (39) 5079-5085
    CrossrefPubMedGoogle Scholar
  • 111 Kim KM, Roh JH, Lee S, Yoon JH. Do renin-angiotensin system inhibitors reduce risk for hepatocellular carcinoma?: A nationwide nested case-control study. Clin Res Hepatol Gastroenterol 2021; 45 (04) 101510
    CrossrefPubMedGoogle Scholar
  • 112 Zhang X, Wong GL, Yip TC. et al. Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. Hepatology 2022; 76 (02) 469-482
    CrossrefPubMedGoogle Scholar
  • 113 Ho CM, Lee CH, Lee MC. et al. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study. BMC Cancer 2018; 18 (01) 401
    CrossrefPubMedGoogle Scholar
  • 114 Yoshiji H, Noguchi R, Toyohara M. et al. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J Hepatol 2009; 51 (02) 315-321
    CrossrefPubMedGoogle Scholar
  • 115 Yoshiji H, Noguchi R, Ikenaka Y. et al. Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial. Oncol Rep 2011; 26 (06) 1547-1553
    PubMedGoogle Scholar
  • 116 Facciorusso A, Del Prete V, Crucinio N. et al. Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients. J Gastroenterol Hepatol 2015; 30 (11) 1643-1650
    CrossrefPubMedGoogle Scholar